VX1 Stock Price, Chart, Stats & News

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily engaged in the development and commercialization of groundbreaking treatments for cystic fibrosis. Its existing portfolio includes therapies such as SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, prescribed for individuals with cystic fibrosis who exhibit particular mutations in their cystic fibrosis transmembrane conductance regulator gene. Additionally, TRIKAFTA is available for CF patients aged six and older possessing at least one F508del mutation.